International Scientific Information, Inc.’s Post

Dear Colleagues, I wanted to bring your attention to a recent publication in the American Journal of Case Reports that shares a rare but potentially life-threatening subtype of Behçet’s disease - Vascular Behçet’s disease (VBD). This subtype primarily affects males with ancestry along the ancient Silk Road and can lead to complications such as aneurysmal degeneration or occlusion in both arteries and veins. The study focuses on a distinctive case of VBD, where a 51-year-old man initially presented with unilateral blue toe syndrome, which quickly progressed to dry gangrene. The report highlights the importance of differentiating between inflammatory microvascular occlusive disease and vasospastic Raynaud’s syndrome, as both can complicate Behçet’s disease. This publication serves as a reminder for the medical community to thoroughly evaluate patients with VBD, particularly in cases of isolated small-vessel vasculitis-induced digital ischemia. The insights gained from this study will undoubtedly aid in improving clinical discernment and patient management. For those interested in delving deeper into this topic, the complete report is now available on the American Journal of Case Reports webpage. | https://lnkd.in/dCp5jD_r

Characteristics and outcomes of over a million inflammatory bowel disease subjects in seven countries: a multinational cohort study #OHDSISocialShowcase Lead: Chen Yanover Team: Ramit Magen-Rimon, Erica Voss, MPH, PMP, Joel Swerdel, Anna Sheahan, Nathan Hall, MS, Jimyung Park, Rae Woong Park, Kwang Jae Lee, Sung Jae Shin, Seung In Seo, Kyung-Joo Lee, Thomas Falconer, Leonard Haas, Paul Nagy, Mary Bowring, Michael Cook, Steven Miller, Tal El-Hay, Maytal Bivas-Benita, Pinchas Akiva, Yehuda Chowers, Roni Weisshof Background: Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases (IBD) with consistently increasing incidence rates worldwide, especially in newly industrialized and developed countries. IBD have significant impact on a patient’s and family’s quality of life, imposing heavy healthcare financial burden due to chronically administered medications, hospitalizations, and surgical procedures. We describe an open Observational Health Data Sciences and Informatics (OHDSI) network study that characterizes IBD patient cohorts to better understand its natural history, risk factors, symptoms, associated comorbidities (including malignancies and extra-intestinal manifestations), treatment pathways, and outcomes. Specifically, we compute the prevalence and aggregate counts of thousands of attributes, in multiple baseline and follow-up time windows, for IBD, CD, UC, and IBD unclassified (IBDU) patient cohorts as well as various strata (e.g., by age group, sex, race). Results for approximately 1.2 million IBD subjects in sixteen databases (DBs) from seven countries – USA, UK, France, Germany, Japan, Korea, and Australia – are freely available through an interactive website and in downloadable formats and can serve as a resource for further exploration and analysis. https://lnkd.in/ecWc959X

Today, the VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health marks October as Liver Awareness Month. Since our founding nearly 2 years ago, we have been working on a three-pronged approach to our research on liver disease and how we are revolutionizing liver care. First, we continue to recruit fellows and faculty working on metabolic health and how it connects to liver injury, inflammation and scarring. Secondly, we are establishing international collaborative partnerships with researchers from different specialties who study diseases that share common biology. By working together, we can share ideas, find new discoveries and develop therapies relevant to a wide array of health issues. Thirdly, we are expanding our expertise in new areas: for example, we now have clinics for illnesses like sarcoidosis, and cholestatic liver disease, in which the bile produced in your liver is slowed or stalled. Above all else, we remain dedicated to patient-centered care. As the Stravitz-Sanyal institute expands, more revolutionary treatment options will become available for patients with liver diseases. #Get2KnowYourLiver #OctoberIs4Livers #liver #VCU

Polycystic Kidney Disease (January 19, 2024)PKD is a severe genetic disorder that can have a devastating impact on kidney function and overall health. Although there is no known cure for this disease, there are proactive steps that individuals can take to manage the symptoms and slow its progression. Early diagnosis and treatment are essential in preserving kidney function and overall health. Collaborating with healthcare providers to develop a comprehensive treatment plan that includes medications, lifestyle changes, and regular monitoring can make a significant difference in the quality of life for those living with PKD. Moreover, supporting ongoing research and clinical trials can lead to new and innovative treatments for PKD. By joining the workshop today, you'll have the opportunity to learn about the latest developments in PKD research and how you can support it. Together, we can work towards improving the lives of those affected by PKD and strive for a future without this debilitating disease. https://lnkd.in/g829i68e

Polycystic Kidney Disease (January 19, 2024)PKD is a severe genetic disorder that can have a devastating impact on kidney function and overall health. Although there is no known cure for this disease, there are proactive steps that individuals can take to manage the symptoms and slow its progression. Early diagnosis and treatment are essential in preserving kidney function and overall health. Collaborating with healthcare providers to develop a comprehensive treatment plan that includes medications, lifestyle changes, and regular monitoring can make a significant difference in the quality of life for those living with PKD. Moreover, supporting ongoing research and clinical trials can lead to new and innovative treatments for PKD. By joining the workshop today, you'll have the opportunity to learn about the latest developments in PKD research and how you can support it. Together, we can work towards improving the lives of those affected by PKD and strive for a future without this debilitating disease. https://lnkd.in/gQ2y5amd

Bronchiectasis is a complicated condition that can result in irreversible lung injury and chronic symptoms like productive cough and recurrent exacerbations. Understanding Cole's vicious cycle hypothesis may be the key to reducing symptom burden and improving care. Join us for an insightful conversation between Drs. Ashwin Basavaraj and Christopher Lippincott about the clinical mechanisms behind bronchiectasis. They're examining the pathophysiology of this condition, highlighting significance of Cole's vicious cycle hypothesis and breaking down the cycle's four components. They discuss the role of inflammation in disease development and progression, illuminate the diagnostic criteria for bronchiectasis, and provide examples of resources you can share with patients to help them understand this condition. Tune in to discover how Cole's vicious hypothesis has significantly altered our clinical understanding of bronchiectasis and hear further insights on care. Optimize bronchiectasis management in your practice: https://ow.ly/UCUh50Qq8Zk

Today is Rare Disease Day, a global movement aimed at raising awareness and understanding of rare diseases and their impact on individuals and families. With approximately 300 million people worldwide living with rare diseases, this day is a reminder of the unique challenges they face in diagnosis, treatment, and everyday life. MAC Clinical Research has worked on a number of clinical trials for rare diseases and conditions that affect fewer than 1 in 2,000 people such as Sickle Cell disease, Idiopathic Pulmonary Fibrosis (IPF), and Alpha-1 Antitrypsin deficiency. We should also take this opportunity to recognise the tireless efforts of carers, researchers, and healthcare professionals dedicated to supporting people living with rare diseases. With greater awareness and collaboration, we can work towards improving access to treatments, advancing research, and ultimately enhancing the quality of life for those affected by rare diseases. If you would like to speak to us about our experience in this area, or would like more information on how we can support your study, contact us here: https://lnkd.in/exxCw9_U #cro #clinicalresearch #RareDiseaseDay #RareDiseaseAwareness 

American Liver Foundation (ALF) Partners with EmpiraMed to launch the first-ever patient registry for all types of liver disease. https://lnkd.in/dZZ9FS66 The new patient registry has a user-friendly platform powered by EmpiraMed, an observational data research company that focuses on registry data through the PRO Portal™ and is available at liverpatientregistry.org. The Patient Registry is hosted in Court Square Group’s Audit Ready Compliant Cloud (#ARCC) and will help provide researchers with a better understanding of liver diseases, the impact of current treatments, and how liver disease affects patients. #HEOR #RWE #ePRO #HealthData #ClinicalTrials #ClinicalResearch #eClinical #eConsent #eCOA #eICF #DCT

Bronchiectasis is a complicated condition that can result in irreversible lung injury and chronic symptoms like productive cough and recurrent exacerbations. Understanding Cole's vicious cycle hypothesis may be the key to reducing symptom burden and improving care. Join us for an insightful conversation between Drs. Ashwin Basavaraj and Christopher Lippincott about the clinical mechanisms behind bronchiectasis. They're examining the pathophysiology of this condition, highlighting significance of Cole's vicious cycle hypothesis and breaking down the cycle's four components. They discuss the role of inflammation in disease development and progression, illuminate the diagnostic criteria for bronchiectasis, and provide examples of resources you can share with patients to help them understand this condition. Tune in to discover how Cole's vicious hypothesis has significantly altered our clinical understanding of bronchiectasis and hear further insights on care. Optimize bronchiectasis management in your practice: https://ow.ly/LizM50Qq8Yv

🌟 New Research Paper Alert! 🌟 The treatment of severe aortic valve stenosis has shifted significantly in favour of transcatheter procedures, even in younger and low-risk patients. This transition brings new considerations for patients with structural valve degeneration (SVD) and infective endocarditis (IE). How should we manage a patient with SVD after SAVR or TAVR? What are the options and what are the issues to consider? What about infective endocarditis (IE)? We have explored these questions in the following paper. Read it and find the right treatment for your patient: https://lnkd.in/ehihTy3k #AorticStenosis #SAVR #TAVR #SVD #InfectiveEndocarditis #MedicalResearch